Host Species:	Goat
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	Human CRP
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity	Specifically binds to human CRP. Dilution for immunoblot and ELISA range: 1,000 to 80,000.
Use:	The antibody can be used for detection of CRP in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

Importance

Human C-Reactive Protein (CRP) is an important biomarker for predicting of future cardiovascular events, such as heart attack and stroke (Koenig et al., 1999, Jenny et al., 2007, Kabagambe et al. 2011). CRP is an acute phase protein produced by the liver. It is a member of the pentraxin family of proteins with five identical nonglycosylated subunits of 206 amino acids each (m.w. 23 kDa) (Agrawal et al., 2009). Among other markers of inflammation, CRP has shown the strongest association with cardiovascular events (Marsik et al., 2008, Kones et al., 2010). Clinical studies demonstrated that coronary mortality among patients with unstable angina and elevated CRP is significantly higher comparing with the patients without elevated CRP. It is an important biomarker for detecting individuals at high risk of plaque rapture.

Agrawal, Alok, Prem Prakash Singh, Barbara Bottazzi, Cecilia Garlanda, and Alberto Mantovani. "Pattern Recognition by Pentraxins." Advances in Experimental Medicine and Biology 653 (2009): 98-116.

Jenny, N. S., N. D. Yanez, B. M. Psaty, L. H. Kuller, C. H. Hirsch, and R. P. Tracy. "Inflammation Biomarkers and Near-Term Death in Older Men." American Journal of Epidemiology 165 (2007): 684-95.

Kabagambe, E. K., S. E. Judd, V. J. Howard, N. A. Zakai, N. S. Jenny, M. Hsieh, D. G. Warnock, and M. Cushman. "Inflammation Biomarkers and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke Cohort." American Journal of Epidemiology 174 (2011): 284-92.

Koenig, W., M. Sund, M. Frohlich, H.-G. Fischer, H. Lowel, A. Doring, W. L. Hutchinson, and M. B. Pepys. "C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men: Results From the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 198." Circulation 99 (1999): 237-42.

Kones, Richard. "Rosuvastatin, Inflammation, C-reactive Protein, JUPITER, and Primary Prevention of Cardiovascular Disease – a Perspective." DDDT Drug Design, Development and Therapy 4 (2010): 383.

Marsik, C., L. Kazemi-Shirazi, T. Schickbauer, S. Winkler, C. Joukhadar, O. F. Wagner, and G. Endler. "C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort." Clinical Chemistry 54 (2008): 343-49.

 

Citations

[A24][A25]

2012

Wang, Min S.; Messersmith, Reid E.; Reed, Scott M. (2012): Membrane curvature recognition by C-reactive protein using lipoprotein mimics. In Soft Matter 8 (30), pp. 7909–7918. DOI: 10.1039/C2SM25779C.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。